Access physician-administered drug pricing and coding information at the HCPCS Unit Level.
Access Self-Administered drug pricing and coding information at the NDC Level.
Monitor all of their product listings on key pricing and coding databases used by payers, pharmacies and providers.
Disease-specific and category-based analytical reports.
From: BuyandBill.com <firstname.lastname@example.org>
Subject: J1932, Lanreotide Injection (Cipla) has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS)
Effective January 1, 2023:
J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G from
The Centers for Medicare and Medicaid (CMS)1
APC Per HCPCS Unit (1 mg)
HCPCS Units Per Package
injection, lanreotide, (Cipla), 1 mg
Lanreotide Acetate Subcutaneous Solution 120/MG/.05mL
Please contact us @ Account.Management@Cipla.com
© Copyright 2023 Cipla USA Inc. All rights reserved
January 2023 CUSAI-09292022-01
References: 1. https://www.cms.gov/license/ama?file=/files/zip/january-2023-opps-addendum-b.zip